Stay updated on Losartan and Nivolumab in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Losartan and Nivolumab in Pancreatic Cancer Clinical Trial page.

Latest updates to the Losartan and Nivolumab in Pancreatic Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe pancreatic cancer trial record is displayed, including its treatment arms, eligibility criteria, study locations, and outcome measures.SummaryDifference75%

- Check19 days agoChange DetectedThe site footer now identifies the ClinicalTrials.gov revision as v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check26 days agoChange DetectedA banner announces that NIH websites are transitioning terminology from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check33 days agoChange DetectedThe footer revision identifier changed from v3.7.1 to v3.7.2; the page continues to show a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check40 days agoChange DetectedThe ClinicalTrials.gov footer now shows revision v3.7.1 instead of v3.7.0.SummaryDifference0.2%

- Check60 days agoChange DetectedThe page now displays a 403 Forbidden error screen, replacing the usual study record content with an access-denied notice.SummaryDifference22%

Stay in the know with updates to Losartan and Nivolumab in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Losartan and Nivolumab in Pancreatic Cancer Clinical Trial page.